Integra Story

IART -  USA Stock  

USD 68.72  0.74  1.07%

As many millenniums are trying to avoid healthcare space, it makes sense to review Integra Lifesciences a little further and try to understand its current market patterns. What exactly are Integra Lifesciences shareholders getting in May? Is the stock current valuation justified for 2021? Here i will cover my perspective on valuation to give Integra private investors a better outlook on taking a position in the stock.
Published over a month ago
View all stories for Integra Lifesciences | View All Stories
Is Integra Lifesciences growth trend slowing down?
The company currently holds 1.75 B in liabilities with Debt to Equity (D/E) ratio of 1.15, which is about average as compared to similar companies. Integra Lifesciences is OVERVALUED at 69.30 per share with modest projections ahead. Earning per share calculations of the firm is based on official Zacks consensus of 6 analysts regarding Integra Lifesciences' future annual earnings. Given the historical accuracy of 88.95%, the future earnings per share of the company is estimated to be 2.8886 with the lowest and highest values of 2.86 and 2.91, respectively. Please note that this consensus of annual earnings estimates for Integra Lifesciences is an estimate of EPS before non-recurring items and including employee stock options expenses.
We determine the current worth of Integra Lifesciences using both absolute as well as relative valuation methodologies to arrive at its intrinsic value. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Integra Lifesciences based exclusively on its fundamental and basic technical indicators. By analyzing Integra Lifesciences's financials, quarterly and monthly indicators, and related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Integra Lifesciences's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Integra Lifesciences. We calculate exposure to Integra Lifesciences's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Integra Lifesciences's related companies.

Integra Lifesciences Investment Alerts

Integra investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring Integra Lifesciences performance across your portfolios.Please check all investment alerts for Integra

Integra Lifesciences Valuation Ratios as Compared to Competition

Our valuation model uses many indicators to compare Integra value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Integra Lifesciences competition to find correlations between indicators driving the intrinsic value of Integra.

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions.
It is good to see analyst projects for Integra Lifesciences, but it might be worth checking our own buy vs. sell analysis

A Deeper Perspective

The modest gains experienced by current holders of Integra Lifesciences may raise some interest from private investors. The stock closed today at a share price of 76.63 on 592,000 in trading volume. The company executives have been quite successful in maneuvering the stock at opportune times to take advantage of all market conditions in March. The stock standard deviation of daily returns for 30 days investing horizon is currently 1.5. The below-average Stock volatility is a good sign for longer-term investment options and for buy-and-hold investors.
 2018 2019 2020 2021 (projected)
Interest Expense64.68 M53.96 M71.58 M57.91 M
Gross Profit900.95 M952.88 M851.03 M817.86 M

Margins Breakdown

Integra profit margins show the degree to which it makes money. Margin indicators are used not only by investors but also by creditors or Integra Lifesciences itself as indicators of financial health and management effectiveness. Please look more closely at the different varieties of Integra Lifesciences profit margins.
Operating Margin10.29
EBITDA Margin0.2
Gross Margin0.68
Profit Margin0.1

Integra Lifesciences Average Assets is increasing over the last 8 years. Also, Integra Lifesciences Earnings Before Interest Taxes and Depreciation Amortization USD is increasing over the last 8 years. The previous year's value of Integra Lifesciences Earnings Before Interest Taxes and Depreciation Amortization USD was 239,695,158.

Integra showing indication of lower volatility

Newest coefficient of variation is at 910.66. Integra Lifesciences has relatively low volatility with skewness of -0.3 and kurtosis of 0.35. However, we advise all investors to independently investigate Integra Lifesciences to ensure all accessible information is consistent with the expectations about its upside potential and future expected returns. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Integra Lifesciences' stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Integra Lifesciences' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Our Final Takeaway

Whereas other companies under the medical devices industry are still a bit expensive, Integra Lifesciences may offer a potential longer-term growth to private investors. While some private investors may not share our view we believe that the current risk-reward utility is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Integra Lifesciences.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Integra Lifesciences. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to